The UK-based biotechnology company, Monument Therapeutics, uses a precision medicine approach to develop drugs for areas of unmet medical need. Their approach involves using proprietary digital biomarkers to identify patients with homogenous underlying neurobiology, allowing for the advancement of neuroscience drugs. They were formed as a spin-out from Cambridge Cognition in 2021 and aim to reduce heterogeneity in patient groups by accurately identifying those who are most likely to respond to a particular treatment. Monument Therapeutics brings digital biomarkers to neuroscience drug development, providing a precision medicine approach in clinical areas of high unmet need.